Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Small study suggests natural HCV clearance is caused by AR3-antibody response

Key clinical point: A strong B-cell response producing cross-genotype and neutralizing antibodies, especially targeting AR3, contributes to hepatitis C virus clearance and long-term immune protection.

Major finding: A high frequency of cross-genotype antibodies was associated with spontaneous clearance of one or multiple HCV infections (P = .03).

Study details: Analysis of the B-cell repertoire of 13 injecting-drug users from the Amsterdam Cohort Study, with follow-up of a median 17.5 years after primary infection.

Disclosures: This study was supported by the Virgo consortium, funded by the Dutch government. Sabrina Merat and several coauthors are employees of AIMM Therapeutics, as well as shareholders.

Citation:

Merat SJ et al. J Hepatol. 2019;71:14-24.